array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2748) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(91) "The cancer tender in Norway: Criticism of the tender process and comparison of cancer drugs" ["snippet_en"]=> string(143) "An analysis of Norway's largest drug tender, the Cancer Tender, with a focus on criticism of the tender process and comparison of cancer drugs." ["url"]=> string(118) "https://www.healthtalk.no/healthtalk/kritiserer-anbudsprosessen-for-kreftlegemidler-en-bekymringsfull-utvikling/192019" ["image_url"]=> string(78) "https://images.businessradar.com/articles/8aeb7f42-7513-4d14-9687-a6a2f322b438" ["source"]=> string(13) "healthtalk.no" ["publication_date"]=> string(10) "2024-11-05" ["categories"]=> array(2) { [0]=> string(5) "Award" [1]=> string(15) "Deals & Tenders" } } [1]=> array(7) { ["title_en"]=> string(90) "Zuellig Pharma joins hands with Regeneron to introduce Libtayo® to Taiwan and South Korea" ["snippet_en"]=> string(558) "Taipei, Taiwan – Media OutReach Newswire – August 28, 2024 – Zuellig Pharma, Asia’s leading pharmaceutical and healthcare services provider, today announced that it has entered into a strategic partnership with Regeneron Pharmaceuticals, Inc., a global biotechnology leader. )'s wholly-owned subsidiary Regeneron Ireland DAC has signed an exclusive distribution agreement to introduce and promote Libtayo® (cemiplimab), a fully human monoclonal antibody targeting the T cell immune checkpoint receptor PD-1, in the Taiwan and South Korean markets. ." ["url"]=> string(220) "https://www.macaubusiness.com/%E8%A3%95%E5%88%A9%E9%86%AB%E8%97%A5-zuellig-pharma-%E6%94%9C%E6%89%8B%E9%9B%B7%E5%82%91%E7%B4%8D%E6%A6%AE-regeneron-%E5%B0%87-libtayo-%E5%B0%8E%E5%85%A5%E5%8F%B0%E7%81%A3%E5%8F%8A%E5%8D%97/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/67a1e965-9cf0-4dae-8942-8ba9769e6451" ["source"]=> string(17) "macaubusiness.com" ["publication_date"]=> string(10) "2024-08-28" ["categories"]=> array(2) { [0]=> string(13) "Collaboration" [1]=> string(15) "Deals & Tenders" } } [2]=> array(7) { ["title_en"]=> string(239) "FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials" ["snippet_en"]=> string(154) "FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO® in..." ["url"]=> string(252) "https://www.globenewswire.com/news-release/2024/06/03/2892583/0/en/FibroGen-Announces-Clinical-Trial-Supply-Agreement-with-Regeneron-Pharmaceuticals-to-Evaluate-FibroGen-s-Immuno-Oncology-Assets-FG-3165-anti-Galectin-9-and-FG-3175-anti-CCR8-in-Com.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/a0565d33-55df-4f3f-a3a9-6946255bdb57" ["source"]=> string(17) "globenewswire.com" ["publication_date"]=> string(10) "2024-06-03" ["categories"]=> array(2) { [0]=> string(13) "Collaboration" [1]=> string(15) "Deals & Tenders" } } [3]=> array(7) { ["title_en"]=> string(116) "Adium announces an exclusive distribution agreement with Regeneron for the commercialization of Cemiplimab in Brazil" ["snippet_en"]=> string(148) "Pharmaceutical company Adium announces exclusive distribution agreement with Regeneron Ireland DAC, a wholly owned subsidiary of Regeneron, for Libt" ["url"]=> string(136) "https://saludnews.net/adium-anuncia-un-acuerdo-de-distribucion-exclusiva-con-regeneron-para-la-comercializacion-de-cemiplimab-en-brasil/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/f9806725-d463-475f-baf3-e64255bac539" ["source"]=> string(13) "saludnews.net" ["publication_date"]=> string(10) "2024-03-30" ["categories"]=> array(2) { [0]=> string(13) "Collaboration" [1]=> string(15) "Deals & Tenders" } } [4]=> array(7) { ["title_en"]=> string(112) "2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron | TSVT Stock News" ["snippet_en"]=> string(229) "2seventy bio, Inc. (Nasdaq: TSVT) has completed an asset purchase agreement with Regeneron Pharmaceuticals, Inc., focusing exclusively on the development and commercialization of Abecma, a CAR T cell therapy for multiple myeloma." ["url"]=> string(115) "https://www.stocktitan.net/news/TSVT/2seventy-bio-announces-completion-of-oncology-and-autoimmune-65ex5m9fekls.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/dd4bdefa-472d-41a7-9009-ab29959775ab" ["source"]=> string(14) "stocktitan.net" ["publication_date"]=> string(10) "2024-03-20" ["categories"]=> array(2) { [0]=> string(13) "Collaboration" [1]=> string(15) "Deals & Tenders" } } [5]=> array(7) { ["title_en"]=> string(30) "GENESIS-PHARMA | Business Wire" ["snippet_en"]=> string(147) "GENESIS Pharma Announces an Exclusive Distribution Agreement With Regeneron Pharmaceuticals to Commercialize cemiplimab in Greece, Cyprus and Malta" ["url"]=> string(88) "https://via.ritzau.dk/pressemeddelelse/13787386/genesis-pharma?publisherId=90456&lang=en" ["image_url"]=> string(78) "https://images.businessradar.com/articles/da91a8de-3b23-4b5e-a877-b5a3d333fcec" ["source"]=> string(9) "ritzau.dk" ["publication_date"]=> string(10) "2024-03-01" ["categories"]=> array(2) { [0]=> string(13) "Collaboration" [1]=> string(15) "Deals & Tenders" } } [6]=> array(7) { ["title_en"]=> string(75) "Regeneron Pharmaceuticals inks $100M deal to develop gene-editing therapies" ["snippet_en"]=> string(117) "The deal gives Regeneron access to Mammoth Biosciences' gene editing systems, which can be used to cut DNA sequences." ["url"]=> string(114) "https://www.crainsnewyork.com/health-pulse/regeneron-pharmaceuticals-inks-100m-deal-develop-gene-editing-therapies" ["image_url"]=> NULL ["source"]=> string(17) "crainsnewyork.com" ["publication_date"]=> string(10) "2024-02-04" ["categories"]=> array(1) { [0]=> string(15) "Deals & Tenders" } } [7]=> array(7) { ["title_en"]=> string(128) "Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries" ["snippet_en"]=> string(158) "/PRNewswire/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international..." ["url"]=> string(182) "https://www.prnewswire.co.uk/news-releases/medison-pharma-announces--agreement-with-regeneron-pharmaceuticals-to-commercialize-libtayo-cemiplimab-in-multiple-countries-302028359.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/a5536b51-142d-4a07-8c9b-f46a94f9b2c2" ["source"]=> string(16) "prnewswire.co.uk" ["publication_date"]=> string(10) "2024-01-08" ["categories"]=> array(3) { [0]=> string(24) "Access and affordability" [1]=> string(13) "Collaboration" [2]=> string(15) "Deals & Tenders" } } [8]=> array(7) { ["title_en"]=> string(69) "Meharry and Big Pharma announce $80 million deal for genetics project" ["snippet_en"]=> string(131) "The investment at Meharry will include the creation of a genetics research center and programs to encourage students to study STEM." ["url"]=> string(136) "https://eu.tennessean.com/story/news/health/2023/10/19/meharry-and-big-pharma-announce-80-million-deal-for-genetics-project/71219652007/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/6eb4cfc7-bed9-48e8-9a36-ac7d25f2131a" ["source"]=> string(14) "tennessean.com" ["publication_date"]=> string(10) "2023-10-19" ["categories"]=> array(4) { [0]=> string(17) "Academic Research" [1]=> string(13) "Collaboration" [2]=> string(15) "Deals & Tenders" [3]=> string(5) "R & D" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(263) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(201) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(196) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(129) } [4]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(116) } [5]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(116) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(93) } [7]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(79) } [8]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(67) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(66) } [10]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(61) } [11]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(59) } [12]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(57) } [13]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(56) } [14]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(53) } [15]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(43) } [16]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(40) } [17]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(38) } [18]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(37) } [19]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(37) } [20]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(37) } [21]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(35) } [22]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(33) } [23]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(32) } [24]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(31) } [25]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(28) } [26]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(28) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(25) } [28]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(21) } [29]=> array(2) { ["name"]=> string(21) "Intellectual Property" ["count"]=> int(20) } } } c469a-us-regeneron-pharmaceuticals-inc